Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Indiana: below-average open trial sites
903 of 3,113 in-state trials are recruiting (29%); below the 37% national average by 8 percentage points.
According to ClinicalTrials.gov-derived indexes, Indiana sits in the upper half of US states by in-state trial count (#21 of 52 states by registered in-state trial count).
Indiana: 3,113 US clinical trials with in-state sites, 903 recruiting.
Indiana has 3,113 registered US clinical trials with a study site in-state, 903 of them currently recruiting (below the 37% national average by 8 percentage points). 793 of these trials are in Phase 3 (late-stage) and 769 in Phase 2. The most frequently studied condition in Indiana is Breast Cancer, with 58 linked trials.
Mid-pack research density
Indiana sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open enrollment
Indiana still shows 903 recruiting of 3,113 in-state trials (29% open), but below the 37% national average by 8 percentage points, so archived statuses weigh heavier than the national baseline.
- 29%
- open (below national share)
- 903
- still recruiting despite cool share
- 769
- Phase 2 rows in this footprint
- 58
- top: Breast Cancer
Recruiting share is below the 37% national average by 8 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Indiana vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
3,113 Top 40% more indexed trials than 60% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Indiana on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Indiana open-enrollment share sits below the national baseline.
903 of 3,113 in-state trials (29%) are recruiting, against 37% nationally (-8 percentage points). Counts include every study with at least one recorded site in the state.
-
Indianapolis dominates Indiana's trial geography.
Indianapolis lists 2,099 of 3,113 in-state trials (67.4%) across 821 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in Indiana.
58 of 3,113 in-state trials (1.9%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
Indiana sponsorship is fragmented across many organizations.
Indiana University appears on 280 of 3,113 in-state trials (9%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,537 Indiana trials carry a completed status.
1,537 of 3,113 (49.4%) are completed. The open share above is the remainder that still lists recruiting.
Where trials run in Indiana
Indianapolis carries 2,099 of Indiana's 3,113 indexed trials (67%) across 821 named sites, ahead of Fort Wayne at 274. 8 cities clear five listed trials, together naming 1,215 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Indianapolis | 2,099 | 821 |
| Fort Wayne | 274 | 135 |
| Carmel | 128 | 66 |
| Evansville | 126 | 62 |
| South Bend | 88 | 44 |
| Bloomington | 74 | 33 |
| West Lafayette | 60 | 17 |
| New Albany | 58 | 37 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share low
Indiana open-enrollment share is 29% (p22 of states with sites; national baseline 37%).
Indiana: open share sits in the low tercile of states
Geography is concentrated: Indianapolis alone accounts for 67% of Indiana's indexed trials (2,099 of 3,113), with Fort Wayne a distant second at 274.
Phase mix: 793 Phase 3 vs 769 Phase 2 (balanced across stages).
Top condition: Breast Cancer (58 trials); top sponsor Indiana University (280).
mid-volume · low-open figures (3,113 trials · 29% open) describe registry geography under the open-share low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Indiana on open-enrollment share
Cross-state peers under the open-share low read (mid-volume · low-open), not the same-state browse list.
Similar mid-volume peers (± open share)
- New Jersey · 3,402 trials · 34% recruiting
- Washington · 2,795 trials · 33% recruiting
- Tennessee · 3,520 trials · 33% recruiting
- Connecticut · 3,531 trials · 32% recruiting
- Virginia · 2,598 trials · 40% recruiting
Similar low-open peers (± trial volume)
- Alabama · 29% recruiting · 4,168 trials
- New Mexico · 29% recruiting · 579 trials
- Kansas · 29% recruiting · 2,080 trials
- Nebraska · 29% recruiting · 1,301 trials
- Arkansas · 28% recruiting · 2,376 trials